(Source: Company Presentation)
GBA Presents: RADIO SAVANT-!
- Thread starter stonedinvestor
- Start date
(Source: Company Presentation)
Of all those stocks that you want to double... KRTX is the one that could, thats why I've been digging, PLUS to help you too... but again... its risky.
I think there is hope that not only schizophrenia can be helped but... $Dementia <------
Dementia-related psychosis is caused by a variety of different diseases and is characterized by the loss of cognitive functioning. Dementia affects more than 8 million people in the United States. Treatment options are limited for psychosis in patients with dementia. Antipsychotics have limited utility, as increased morbidity and mortality is observed when used on the elderly.
Dementia-related psychosis is caused by a variety of different diseases and is characterized by the loss of cognitive functioning. Dementia affects more than 8 million people in the United States. Treatment options are limited for psychosis in patients with dementia. Antipsychotics have limited utility, as increased morbidity and mortality is observed when used on the elderly.
Oh if it gets approved... friggin JACKPOT!!I think there is hope that not only schizophrenia can be helped but... $Dementia <------
Dementia-related psychosis is caused by a variety of different diseases and is characterized by the loss of cognitive functioning. Dementia affects more than 8 million people in the United States. Treatment options are limited for psychosis in patients with dementia. Antipsychotics have limited utility, as increased morbidity and mortality is observed when used on the elderly.
--over the past 5 years, bluebird stock has declined in value by 95%.
-- When gene editing first popped up BLUE was there-
--bluebird - originally founded as Genetix Pharmaceuticals in 1992, was the first gene therapy company to successfully achieve the long-term correction of a human genetic disease, when a patient with beta-thalassemia - a blood-disorder caused by the mutation of the HBB gene that reduces the production of hemoglobin, causing life threatening complications - was "functionally cured", no longer requiring regular blood transfusions, which is the standard of care treatment for the disease.
Despite this early success, and a listing on the Nasdaq in 2013, a decade later bluebird has not been able to commercialise a single drug in the US.
Over the past few years, the emergence of CRISPR technology - genetic scissors that splice DNA, enabling edits or corrections to be made to faulty genes - has put bluebird and its older, lentiviral based gene addition platform somewhat in the shade.
>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>
My sense is after a spurt there has been some slowdown in CRSPR-based treatments perhaps due to side effects or other dangers. I hear some negative CRSPR talk when it used to be all positive... can the older forgotten lentiviral method regain some footing here?... a safer way perhaps?
-- When gene editing first popped up BLUE was there-
--bluebird - originally founded as Genetix Pharmaceuticals in 1992, was the first gene therapy company to successfully achieve the long-term correction of a human genetic disease, when a patient with beta-thalassemia - a blood-disorder caused by the mutation of the HBB gene that reduces the production of hemoglobin, causing life threatening complications - was "functionally cured", no longer requiring regular blood transfusions, which is the standard of care treatment for the disease.
Despite this early success, and a listing on the Nasdaq in 2013, a decade later bluebird has not been able to commercialise a single drug in the US.
Over the past few years, the emergence of CRISPR technology - genetic scissors that splice DNA, enabling edits or corrections to be made to faulty genes - has put bluebird and its older, lentiviral based gene addition platform somewhat in the shade.
>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>
My sense is after a spurt there has been some slowdown in CRSPR-based treatments perhaps due to side effects or other dangers. I hear some negative CRSPR talk when it used to be all positive... can the older forgotten lentiviral method regain some footing here?... a safer way perhaps?
AUG 19
bluebird bio and beti-cel and eli-cel.
Bluebird (NASDAQ:BLUE) could be singing happy notes in August and September if the FDA approves these lentiviral vector (LVV)-based gene therapies. The action dates for beti-cel and eli-cel are, respectively, Aug. 19 and Sept. 16.
Prospects are good for approval after an FDA panel backed both therapies in June.
Beti-cel is for β-thalassemia, a rare blood disorder, while eli-cel is for the rare neurodegenerative disorder cerebral adrenoleukodystrophy.
The treatments could have peak sales of $100M each.
What we don't like " rare " disorders <----
What we do like --> a stk down 90% with some amount of promise.
Certainly $10 is not to much for BLUE with 2 approvals (if they get the FDA knod) and $200 mln in possible sales//
I would even argue $12-$15.
CURRENT PRICE-$3.90
bluebird bio and beti-cel and eli-cel.
Bluebird (NASDAQ:BLUE) could be singing happy notes in August and September if the FDA approves these lentiviral vector (LVV)-based gene therapies. The action dates for beti-cel and eli-cel are, respectively, Aug. 19 and Sept. 16.
Prospects are good for approval after an FDA panel backed both therapies in June.
Beti-cel is for β-thalassemia, a rare blood disorder, while eli-cel is for the rare neurodegenerative disorder cerebral adrenoleukodystrophy.
The treatments could have peak sales of $100M each.
What we don't like " rare " disorders <----
What we do like --> a stk down 90% with some amount of promise.
Certainly $10 is not to much for BLUE with 2 approvals (if they get the FDA knod) and $200 mln in possible sales//
I would even argue $12-$15.
CURRENT PRICE-$3.90
Innoviz Technologies soars after landing contract with Volkswagen
Aug. 02, 2022 7:50 AM ET Innoviz Technologies Ltd. (INVZ)
Israeli lidar maker Innoviz Technologies Ltd. (NASDAQ:INVZ) announced adesign winwith Volkswagen's software company.
CARIAD SE selected Innoviz (INVZ) to be its supplier and deliverer of advanced ADAS features for the segment on automated vehicleswithin the Volkswagen brands.
The deal will run for eight years starting mid-decade and Innoviz (INVZ) expects to supply lidar units for between 5M and 8M Volkswagen vehicles over the contract.
Innoviz (INVZ) said the new contract is its third design win with a major automaker. Innoviz's forward-looking order book was updated to $6.6B.
Shares of INVZ shot up21.25%premarket on Tuesday to $4.25 after the announcement.
Aug. 02, 2022 7:50 AM ET Innoviz Technologies Ltd. (INVZ)
Israeli lidar maker Innoviz Technologies Ltd. (NASDAQ:INVZ) announced adesign winwith Volkswagen's software company.
CARIAD SE selected Innoviz (INVZ) to be its supplier and deliverer of advanced ADAS features for the segment on automated vehicleswithin the Volkswagen brands.
The deal will run for eight years starting mid-decade and Innoviz (INVZ) expects to supply lidar units for between 5M and 8M Volkswagen vehicles over the contract.
Innoviz (INVZ) said the new contract is its third design win with a major automaker. Innoviz's forward-looking order book was updated to $6.6B.
Shares of INVZ shot up21.25%premarket on Tuesday to $4.25 after the announcement.